Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Other financing activities (2016 - 2019)

Sangamo Therapeutics (SGMO) has 4 years of Other financing activities data on record, last reported at $216000.0 in Q1 2019.

  • For Q1 2019, Other financing activities fell 97.96% year-over-year to $216000.0; the TTM value through Sep 2021 reached $216000.0, down 99.16%, while the annual FY2021 figure was $943000.0, N/A changed from the prior year.
  • Other financing activities reached $216000.0 in Q1 2019 per SGMO's latest filing, down from $10.6 million in the prior quarter.
  • Across five years, Other financing activities topped out at $15.0 million in Q4 2017 and bottomed at -$1.0 million in Q4 2016.
  • Average Other financing activities over 4 years is $6.2 million, with a median of $5.4 million recorded in 2018.
  • Peak YoY movement for Other financing activities: soared 1580.59% in 2017, then crashed 97.96% in 2019.
  • A 4-year view of Other financing activities shows it stood at -$1.0 million in 2016, then skyrocketed by 1580.59% to $15.0 million in 2017, then fell by 29.57% to $10.6 million in 2018, then plummeted by 97.96% to $216000.0 in 2019.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $216000.0 in Q1 2019, $10.6 million in Q1 2018, and $15.0 million in Q4 2017.